Anti-PD1L1/ PD-L1/ CD274 monoclonal antibody

Anti-PD1L1/ PD-L1/ CD274 antibody for FACS & in-vivo assay

Target products collectionGo to PD-L1/CD274 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T99948-Ab-1/ GM-Tg-hg-T99948-Ab-2Anti-Human PD-L1/CD274 monoclonal antibodyHuman
GM-Tg-rg-T99948-Ab-1/ GM-Tg-rg-T99948-Ab-2Anti-Rat PD-L1/CD274 monoclonal antibodyRat
GM-Tg-mg-T99948-Ab-1/ GM-Tg-mg-T99948-Ab-2Anti-Mouse PD-L1/CD274 monoclonal antibodyMouse
GM-Tg-cynog-T99948-Ab-1/ GM-Tg-cynog-T99948-Ab-2Anti-Cynomolgus/ Rhesus macaque PD-L1/CD274 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T99948-Ab-1/ GM-Tg-felg-T99948-Ab-2Anti-Feline PD-L1/CD274 monoclonal antibodyFeline
GM-Tg-cang-T99948-Ab-1/ GM-Tg-cang-T99948-Ab-2Anti-Canine PD-L1/CD274 monoclonal antibodyCanine
GM-Tg-bovg-T99948-Ab-1/ GM-Tg-bovg-T99948-Ab-2Anti-Bovine PD-L1/CD274 monoclonal antibodyBovine
GM-Tg-equg-T99948-Ab-1/ GM-Tg-equg-T99948-Ab-2Anti-Equine PD-L1/CD274 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T99948-Ab-1/ GM-Tg-hg-T99948-Ab-2; GM-Tg-rg-T99948-Ab-1/ GM-Tg-rg-T99948-Ab-2;
GM-Tg-mg-T99948-Ab-1/ GM-Tg-mg-T99948-Ab-2; GM-Tg-cynog-T99948-Ab-1/ GM-Tg-cynog-T99948-Ab-2;
GM-Tg-felg-T99948-Ab-1/ GM-Tg-felg-T99948-Ab-2; GM-Tg-cang-T99948-Ab-1/ GM-Tg-cang-T99948-Ab-2;
GM-Tg-bovg-T99948-Ab-1/ GM-Tg-bovg-T99948-Ab-2; GM-Tg-equg-T99948-Ab-1/ GM-Tg-equg-T99948-Ab-2
Products NameAnti-PD-L1/CD274 monoclonal antibody
Formatmab
Target NamePD-L1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-PD-L1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-422Pre-Made Pacmilimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-040Pre-Made Avelumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-INN-972Pre-Made Retlirafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) extracellular fragment (20-136) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1
    BiosimilarGMP-Bios-ab-034Pre-Made Atezolizumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-159Pre-Made Durvalumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-534Pre-Made Sugemalimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-409Pre-Made Opucolimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-188Pre-Made Envafolimab biosimilar, Single Domain Variable Fragment;H, Anti-CD274/PD-L1 Antibody: Anti-B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1 therapeutic antibody
    BiosimilarGMP-Bios-ab-533Pre-Made Sudubrilimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-071Pre-Made Bintrafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-481Pre-Made Retlirafusp biosimilar, Whole mAb Fusion, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-698Pre-Made Tagitanlimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-INN-797Pre-Made Davoceticept Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1
    BiosimilarGMP-Bios-ab-121Pre-Made Cosibelimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-INN-762Pre-Made Bintrafusp Alfa Biosimilar, Fusion Protein targeting CD274/PD-L1 fused with human TGFBR2 (transforming growth factor beta receptor 2) (1:2) via a peptidyl linker: Recombinant therapeutic protein targeting B7-H/B7H1/PDCD1L1/PDCD1LG1
    BiosimilarGMP-Bios-ab-317Pre-Made Lodapolimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-194Pre-Made Erfonrilimab biosimilar, Bispecific Single Domains (VH-VH'-CH), Anti-CD274/PD-L1;CTLA4/CTLA-4 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
    BiosimilarGMP-Bios-ab-010Pre-Made Adebrelimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-693Pre-Made Simridarlimab biosimilar, Whole mAb, Anti-CD47;CD274/PD-L1 Antibody: Anti-IAP/OA3/MER6;B7-H/B7H1/PD-L1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1 therapeutic antibody
    BiosimilarGMP-Bios-ab-235Pre-Made Garivulimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-695Pre-Made Socazolimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    BiosimilarGMP-Bios-ab-007Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibod: Anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody
    BiosimilarGMP-Bios-ab-334Pre-Made Manelimab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species PD1L1/ PD-L1/ CD274 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMLV000121human CD274 Lentivirus particle
    ORF Viral VectorpGMLV000121human CD274 Lentivirus plasmid
    ORF Viral VectorvGMLV000749human CD274 Lentivirus particle
    ORF Viral VectorvGMLV000710human CD274 Lentivirus particle
    ORF Viral VectorpGMLV000710human CD274 Lentivirus plasmid
    ORF Viral VectorpGMLV000749human CD274 Lentivirus plasmid
    ORF Viral VectorpGMLPm000313mouse Cd274 Lentivirus plasmid
    ORF Viral VectorvGMLPm000313mouse Cd274 Lentivirus particle


    Target information

    Target IDGM-T99948
    Target NamePD-L1
    Gene ID29126,60533,499342,716043,484186,100127110,533834,100051703
    Gene Symbol and SynonymsA530045L16Rik,B7-H,B7H1,CD274,hPD-L1,PD-L1,PDCD1L1,PDCD1LG1,PDL1,RGD1566211
    Uniprot AccessionQ9NZQ7
    Uniprot Entry NamePD1L1_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    DiseaseCancer
    Gene EnsemblENSG00000120217
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: PD-L1, gene name: CD274, also named as B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1. This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.